

FIG. 1A







FIG. 1B

*FIG. 1C*

**FIG. 1D**




FIG. 1E




FIG. 1F

COMPOUND (#)	INORGANIC PHOSPHORUS (nmoles)	DENSITY ON TLC (ARBITRARY UNITS)	PHOSPHORUS / DENSITY
VI	8.77	1.75	5.01
VII	4.10	1.52	2.70
VIII	7.34	2.80	2.62

INORGANIC PHOSPHORUS / SCANNING DENSITOMETRY: COMPOUND VI / COMPOUND VII = 1.86
COMPOUND VI / COMPOUND VIII = 1.91

THESE RATIOS INDICATE THAT: a) COMPOUND VI IS A DPHOSPHATE, AND
b) COMPOUND VII & VIII ARE MONOPHOSPHATES.

FIG. 1G




FIG. 2A





FIG. 2B

*FIG. 2C*




FIG. 2D

<u>PMN LIPID</u>	<u>TLC¹:</u> R _f /DOL-P R _f	<u>GCMS²:</u> DIRECT INJECTION	OTMS DERIVATIVE	ACID HYDROLYSIS TO SQUALENE	<u>PHOSPHORUS³:</u> nmoles/10 ⁷ PMN	<u>PROPOSED STRUCTURE:</u>
COMPOUND V	0.14 (±0.02)	4.39 MIN: 235, 327, 261, 232, 220, 205, 189, 177, 91, 69	NP	—	0.11 (±0.04)	FARNESYL- DIPHOSPHATE *
COMPOUND VI	0.25 (±0.02)	8.81 MIN: 489, 447, 410, 341, 273, 205, 191, 136, 95, 81, 69	2.28 MIN: 486, 441, 405, 361	+	1.67 (±0.32)	PRESQUALENE- DIPHOSPHATE
COMPOUND VII	0.44(±0.03)	NP	5.72 MIN: 356, 341, 313, 281, 207, 191, 145, 117, 97, 73, 69	—	0.35 (±0.13)	FARNESYL- MONOPHOSPHATE *
COMPOUND VIII	0.66 (±0.04)	8.81 MIN: 481, 403, 342, 268, 177, 136, 95, 81, 69	9.15 MIN: 486, 441, 403, 361	—	0.47 (±0.12)	PRESQUALENE- MONOPHOSPHATE

FIG. 2E




FIG. 3A




FIG. 3B

12/18




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D





FIG. 4E




PSDP (COMPOUND VI)



- INHIBITION OF O_2^- GENERATION
- INHIBITION OF HOMOTYPIC ADHESION
- INHIBITION OF IP_3 INFORMATION


PSMP (COMPOUND VIII)

INACTIVE

FIG. 4F

**FIG. 5**

**FIG. 6****FIG. 7**

**FIG. 8**